Emerging paradigms in nanostructured targeted drug delivery systems
Source abstract
Abstract
Nanostructured drug delivery systems have emerged as powerful and versatile approaches to overcome the limitations of conventional therapeutic strategies, including poor bioavailability, non-specific distribution, and dose-limiting toxicity. By enabling precise control over particle size, surface characteristics, drug loading, and release kinetics, nanocarriers offer enhanced pharmacokinetic and pharmacodynamic performance, along with improved therapeutic specificity. This comprehensive review critically examines emerging paradigms in Nanostructured drug delivery systems, with a particular focus on design strategies, surface functionalization, and translational potential for targeted therapeutics. The review systematically discusses the fundamental principles governing nanocarrier behavior, including physicochemical characteristics, nano-bio interactions, and pharmacokinetic considerations. Various classes of Nanostructured drug delivery systems-such as lipid-based, polymeric, inorganic, carbon-based, and biomimetic carriers-are evaluated with respect to their design rationale, advantages, and limitations. Advanced targeting strategies, including passive and active targeting, ligand-based functionalization, and stealth modifications, are highlighted for their role in enhancing site-specific delivery and therapeutic efficacy. Furthermore, the review explores cellular uptake mechanisms, intracellular trafficking, and subcellular targeting, providing insights into how nanocarriers can be engineered to overcome biological barriers. The translational landscape of nanomedicine is critically assessed, addressing preclinical evaluation, clinical development, manufacturing scalability, regulatory challenges, and safety considerations. Emerging trends, such as artificial intelligence-assisted nanocarrier design, stimuli-responsive systems, bioinspired platforms, and personalized nanomedicine, are also discussed as future directions. In summary, this review underscores the significant progress and remaining challenges in the field of Nanostructured drug delivery systems and highlights their transformative potential in advancing targeted therapeutics and precision medicine.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Mullick Chowdhury S, et al. Nanoparticles in cancer immunotherapy. Nat Nanotechnol. 2021;16:1160–71. https://doi.org/10.1038/s41565-021-00966-0.10.1038/s41565-021-00966-0 ↗
2. Patra JK, Das G, Fraceto LF, et al. Nano-based drug delivery systems for improving phytochemical bioavailability. J Nanobiotechnology. 2023;21:112. https://doi.org/10.1186/s12951-023-01876-2.10.1186/s12951-023-01876-2 ↗
3. Benet LZ, Hosey CM, Ursu O, Oprea TI. BDDCS, the rule of 5 and drugability. Adv Drug Deliv Rev. 2016;101:89–98. https://doi.org/10.1016/j.addr.2016.05.007.10.1016/j.addr.2016.05.007 ↗
4. Riley RS, et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2020;18:175–96. https://doi.org/10.1038/s41573-018-0006-z.10.1038/s41573-018-0006-z ↗
5. Hsu CY, Rheima AM, Kadhim MM, et al. An overview of nanoparticles in drug delivery: properties and applications. S Afr J Chem Eng. 2023;46:233–70. https://doi.org/10.1016/j.sajce.2023.08.009.10.1016/j.sajce.2023.08.009 ↗
6. Malik S, Muhammad K, Waheed Y. Emerging applications of nanotechnology in healthcare and medicine. Molecules. 2023;28(18):6624. https://doi.org/10.3390/molecules28186624.10.3390/molecules28186624 ↗
7. Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193. https://doi.org/10.3390/molecules25092193.10.3390/molecules25092193 ↗
8. Tripathi D, Pandey P, Sharma S, Rai AK, Prabhu BHM. Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity. BioImpacts. 2024. https://doi.org/10.34172/bi.30573.10.34172/bi.30573 ↗
9. Parodi A, et al. Synthetic nanoparticles for targeting tumors. Nat Nanotechnol. 2020;15:114–24. https://doi.org/10.1038/s41565-019-0619-7.10.1038/s41565-019-0619-7 ↗
10. Srivastava A, Ahmad A, Siddiqui S, Islam A. Innovations in targeted drug delivery: from nanotechnology to clinical applications. Next Nanotechnology. 2026;9:100336. https://doi.org/10.1016/j.nxnano.2025.100336.10.1016/j.nxnano.2025.100336 ↗
11. Rangel-Rojo R, Kassab LRP, Cesca T. Editorial for the special issue on nanomaterials photonics. Micromachines. 2024;15(10):1268. https://doi.org/10.3390/mi15101268.10.3390/mi15101268 ↗
12. Elzein B. Nano revolution: tiny tech, big impact: how nanotechnology is driving SDGs progress. Heliyon. 2024;10(10):e31393. https://doi.org/10.1016/j.heliyon.2024.e31393.10.1016/j.heliyon.2024.e31393 ↗
13. Batty CJ, Bachelder EM, Ainslie KM. Historical perspective of clinical nano and microparticle formulations for delivery of therapeutics. Trends Mol Med. 2021;27(6):516–9. https://doi.org/10.1016/j.molmed.2021.04.002.10.1016/j.molmed.2021.04.002 ↗
14. Mehner F, Bukane AR, Keddie DJ, et al. RAFT enables controlled radical ring-opening polymerisation of cyclic ketene acetals for degradable nanoparticles. Commun Chem. 2026;9(1):156. https://doi.org/10.1038/s42004-026-01997-6.10.1038/s42004-026-01997-6 ↗
15. Shin SW, Yuk JS, Chun SH, Lim YT, Um SH. Hybrid material of structural DNA with inorganic compound: synthesis, applications, and perspective. Nano Converg. 2020;7(1):2. https://doi.org/10.1186/s40580-019-0211-4.10.1186/s40580-019-0211-4 ↗
16. Narayanan K, Bhaskar R, Han S. Recent advances in the biomedical applications of functionalized nanogels. Pharmaceutics. 2022;14(12):2832. https://doi.org/10.3390/pharmaceutics14122832.10.3390/pharmaceutics14122832 ↗
17. Durgam LK, Oroszi TL. Revolutionizing healthcare: the transformative potential of nanotechnology in medicine. Frontiers in Drug Delivery. 2025. https://doi.org/10.3389/fddev.2025.1556426.10.3389/fddev.2025.1556426 ↗
18. Malyshev V, Gab A, Kovalenko V, Pryshedko O, Shakhnin D. Estimation of global nanomedicine market: status, segment analysis, dynamics, competition and prospects. Technology audit and production reserves. 2024;1(4(75)):48–59. https://doi.org/10.15587/2706-5448.2024.299271.10.15587/2706-5448.2024.299271 ↗
19. Sarhan OM. Recent trends in drug delivery systems. Assay Drug Dev Technol. 2026;24(1):2–29. https://doi.org/10.1089/adt.2025.031.10.1089/adt.2025.031 ↗
20. Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence. Pharmaceutics. 2022;14(4):883. https://doi.org/10.3390/pharmaceutics14040883.10.3390/pharmaceutics14040883 ↗
21. Lu H, Zhang S, Wang J, Chen Q. A review on polymer and lipid-based nanocarriers and its application to nano-pharmaceutical and food-based systems. Front Nutr. 2021. https://doi.org/10.3389/fnut.2021.783831.10.3389/fnut.2021.783831 ↗
22. Jayaraj S, Jayaprakash N, Devaraji M, Murugavel S, Robinson AX, Murugesan L. Nanocarrier-based strategies for advanced cancer drug delivery and therapeutics: design principles, biological interactions, and clinical potential. Nano Trends. 2026;14:100203. https://doi.org/10.1016/j.nwnano.2026.100203.10.1016/j.nwnano.2026.100203 ↗
23. Song X, Liu P, Zhang X, et al. In silico methods, simulations, and design of drug‐delivery nanocarriers. Adv Funct Mater. 2026. https://doi.org/10.1002/adfm.202523068.10.1002/adfm.202523068 ↗
24. Xu M, Qi Y, Liu G, Song Y, Jiang X, Du B. Size-dependent in vivo transport of nanoparticles: implications for delivery, targeting, and clearance. ACS Nano. 2023;17(21):20825–49. https://doi.org/10.1021/acsnano.3c05853.10.1021/acsnano.3c05853 ↗
25. Ewii UE, Attama AA, Olorunsola EO, et al. Nanoparticles for drug delivery: insight into in vitro and in vivo drug release from nanomedicines. Nano TransMed. 2025;4:100083. https://doi.org/10.1016/j.ntm.2025.100083.10.1016/j.ntm.2025.100083 ↗
26. Öztürk K, Kaplan M, Çalış S. Effects of nanoparticle size, shape, and zeta potential on drug delivery. Int J Pharm. 2024;666:124799. https://doi.org/10.1016/j.ijpharm.2024.124799.10.1016/j.ijpharm.2024.124799 ↗
27. Wang X, Song X, Feng W, Chang M, Yang J, Chen Y. Advanced nanomedicines for treating refractory inflammation-related diseases. Nano-Micro Lett. 2025;17(1):323. https://doi.org/10.1007/s40820-025-01829-7.10.1007/s40820-025-01829-7 ↗
28. Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021;26(19):5905. https://doi.org/10.3390/molecules26195905.10.3390/molecules26195905 ↗
29. Dwivedi K, Sahoo A, Almalki WH, et al. Innovative nanocarrier systems for enhanced delivery of phyto-active compounds in cancer therapy. Nanomedicine. 2025;20(1):91–116. https://doi.org/10.1080/17435889.2024.2440301.10.1080/17435889.2024.2440301 ↗
30. Pirhaghi M, Mamashli F, Moosavi-Movahedi F, et al. Cell-penetrating peptides: promising therapeutics and drug-delivery systems for neurodegenerative diseases. Mol Pharm. 2024;21(5):2097–117. https://doi.org/10.1021/acs.molpharmaceut.3c01167.10.1021/acs.molpharmaceut.3c01167 ↗
31. Shahid U. Advances in RNA therapeutics: classes, innovations and clinical applications. The Journal of Precision Medicine: Health and Disease. 2025;3:100016. https://doi.org/10.1016/j.premed.2025.100016.10.1016/j.premed.2025.100016 ↗
32. Yang Y, Wang Z, Peng Y, Ding J, Zhou W. A smart pH-sensitive delivery system for enhanced anticancer efficacy via Paclitaxel endosomal escape. Front Pharmacol. 2019. https://doi.org/10.3389/fphar.2019.00010.10.3389/fphar.2019.00010 ↗
33. Neves BS, Gonçalves RC, Mano JF, Oliveira MB. Controlling the diffusion of small molecules from matrices processed by all-aqueous methodologies: towards the development of green pharmaceutical products. Green Chem. 2024;26(8):4417–31. https://doi.org/10.1039/D3GC04183B.10.1039/D3GC04183B ↗
34. Glassman PM, Muzykantov VR. Pharmacokinetic and pharmacodynamic properties of drug delivery systems. J Pharmacol Exp Ther. 2019;370(3):570–80. https://doi.org/10.1124/jpet.119.257113.10.1124/jpet.119.257113 ↗
35. Duan D, Wang A, Ni L, et al. Trastuzumab- and Fab′ fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo. Int J Nanomedicine. 2018;13:1831–40. https://doi.org/10.2147/IJN.S153795.10.2147/IJN.S153795 ↗
36. Zou H, Banerjee P, Leung SSY, Yan X. Application of pharmacokinetic-pharmacodynamic modeling in drug delivery: development and challenges. Front Pharmacol. 2020. https://doi.org/10.3389/fphar.2020.00997.10.3389/fphar.2020.00997 ↗
37. Decker C, Schubert H, May S, Fahr A. Pharmacokinetics of temoporfin-loaded liposome formulations: correlation of liposome and temoporfin blood concentration. J Control Release. 2013;166(3):277–85. https://doi.org/10.1016/j.jconrel.2013.01.005.10.1016/j.jconrel.2013.01.005 ↗
38. Ahmed TA, Al-Abd AM. Effect of finasteride particle size reduction on its pharmacokinetic, tissue distribution and cellular permeation. Drug Deliv. 2018;25(1):555–63. https://doi.org/10.1080/10717544.2018.1440446.10.1080/10717544.2018.1440446 ↗
39. Ait-Oudhia S, Zhang W, Mager DE. A mechanism-based PK/PD model for hematological toxicities induced by antibody-drug conjugates. AAPS J. 2017;19(5):1436–48. https://doi.org/10.1208/s12248-017-0113-5.10.1208/s12248-017-0113-5 ↗
40. Lucey M, Pickford P, Bitsi S, et al. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists. Mol Metab. 2020;37:100991. https://doi.org/10.1016/j.molmet.2020.100991.10.1016/j.molmet.2020.100991 ↗
41. Zhou R, Mazurchuk RV, Tamburlin JH, Harrold JM, Mager DE, Straubinger RM. Differential pharmacodynamic effects of Paclitaxel formulations in an intracranial rat brain tumor model. J Pharmacol Exp Ther. 2010;332(2):479–88. https://doi.org/10.1124/jpet.109.160044.10.1124/jpet.109.160044 ↗
42. Funk F, Flühmann B, Barton AE. Criticality of surface characteristics of intravenous iron–carbohydrate nanoparticle complexes: implications for pharmacokinetics and pharmacodynamics. Int J Mol Sci. 2022;23(4):2140. https://doi.org/10.3390/ijms23042140.10.3390/ijms23042140 ↗
43. Hassan SA. Strong dependence of the nano-bio interactions on core morphology and layer composition of ultrasmall nanostructures. J Chem Phys. 2019. https://doi.org/10.1063/1.5115192.10.1063/1.5115192 ↗
44. Hassan SA. Artificial neural networks for the inverse design of nanoparticles with preferential nano-bio behaviors. J Chem Phys. 2020. https://doi.org/10.1063/5.0013990.10.1063/5.0013990 ↗
45. Mazayen ZM, Ghoneim AM, Elbatanony RS, Basalious EB, Bendas ER. Pharmaceutical nanotechnology: from the bench to the market. Futur J Pharm Sci. 2022;8(1):12. https://doi.org/10.1186/s43094-022-00400-0.10.1186/s43094-022-00400-0 ↗
46. Mehta M, Bui TA, Yang X, Aksoy Y, Goldys EM, Deng W. Lipid-based nanoparticles for drug/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development. ACS Mater Au. 2023;3(6):600–19. https://doi.org/10.1021/acsmaterialsau.3c00032.10.1021/acsmaterialsau.3c00032 ↗
47. Torchilin VP. Recent advances in liposome-based drug delivery. Nat Rev Drug Discov Published online. 2020. https://doi.org/10.1038/s41573-019-0055-7.10.1038/s41573-019-0055-7 ↗
48. Zhang H, et al. Liposome-based drug delivery systems in cancer therapy. Int J Pharm. 2022;620:121742. https://doi.org/10.1016/j.ijpharm.2022.121742.10.1016/j.ijpharm.2022.121742 ↗
49. Souto EB, Doktorovova S. Solid lipid nanoparticles in drug delivery. Adv Drug Deliv Rev. 2020;154–155:10–9.
50. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach. Indian J Pharm Sci. 2020;82(1):1–13.
51. Li H, et al. Lipid-based nanocarriers in cancer therapy. Int J Nanomedicine. 2021;16:4563–78. https://doi.org/10.2147/IJN.S312345.10.2147/IJN.S312345 ↗
52. Huang ZR, Hua SC, Yang YL, Fang JY. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin. 2008;29(9):1094–102. https://doi.org/10.1111/j.1745-7254.2008.00829.x.10.1111/j.1745-7254.2008.00829.x ↗
53. Haider M, Zaki KZ, El Hamshary MR, Hussain Z, Orive G, Ibrahim HO. Polymeric nanocarriers: a promising tool for early diagnosis and efficient treatment of colorectal cancer. J Adv Res. 2022;39:237–55. https://doi.org/10.1016/j.jare.2021.11.008.10.1016/j.jare.2021.11.008 ↗
54. Malviya R, Srivastava P. Natural polymers in drug delivery: mucilage and gums. J Drug Deliv Sci Technol. 2020;55:101389.
55. Forenzo C, Arnold N, Larsen J. Emerging polymeric nanocarriers for mRNA and protein therapeutics: design, challenges, and clinical outlook. Nanomedicine. 2025;20(18):2357–74. https://doi.org/10.1080/17435889.2025.2542110.10.1080/17435889.2025.2542110 ↗
56. Cho S, Rasoulianboroujeni M, Kang RH, Kwon GS. From conventional to next-generation strategies: recent advances in polymeric micelle preparation for drug delivery. Pharmaceutics. 2025;17(10):1360. https://doi.org/10.3390/pharmaceutics17101360.10.3390/pharmaceutics17101360 ↗
57. Harini A, Perumal I. Polymeric nanomaterials as a drug delivery system for anticancer and antibacterial infections: a review. RSC Adv. 2025;15(39):32572–92. https://doi.org/10.1039/D5RA01788B.10.1039/D5RA01788B ↗
58. Adnan Raza M, Firdous A, Gupta U, Patil U, Singh A, Ajazuddin. Emerging trends in designing the dendrimer-based drug delivery for antineoplastic therapies. ACS Appl Bio Mater. 2025;8(7):5462–95. https://doi.org/10.1021/acsabm.5c00498.10.1021/acsabm.5c00498 ↗
59. Mousavi N, Keshtiara P, Daryanavard M. Hexabranched dendrimers encapsulated metallic copper nanoparticles and their catalytic evaluation for the conversion of para -nitrophenol to para -aminophenol. Inorg Nano-Met Chem. 2025;55(2):152–61. https://doi.org/10.1080/24701556.2023.2240790.10.1080/24701556.2023.2240790 ↗
60. Parvin N, Aslam M, Joo SW, Mandal TK. Nano-Phytomedicine: harnessing plant-derived phytochemicals in nanocarriers for targeted human health applications. Molecules. 2025;30(15):3177. https://doi.org/10.3390/molecules30153177.10.3390/molecules30153177 ↗
61. Bansal SA, Kumar V, Karimi J, Singh AP, Kumar S. Role of gold nanoparticles in advanced biomedical applications. Nanoscale Adv. 2020;2(9):3764–87. https://doi.org/10.1039/D0NA00472C.10.1039/D0NA00472C ↗
62. Eker F, Akdaşçi E, Duman H, Bechelany M, Karav S. Gold nanoparticles in nanomedicine: unique properties and therapeutic potential. Nanomaterials (Basel). 2024;14(22):1854. https://doi.org/10.3390/nano14221854.10.3390/nano14221854 ↗
63. Stiufiuc GF, Stiufiuc RI. Magnetic nanoparticles: synthesis, characterization, and their use in biomedical field. Appl Sci (Basel). 2024;14(4):1623. https://doi.org/10.3390/app14041623.10.3390/app14041623 ↗
64. Roy I, Kritika. Therapeutic applications of magnetic nanoparticles: recent advances. Mater Adv. 2022;3(20):7425–44. https://doi.org/10.1039/D2MA00444E.10.1039/D2MA00444E ↗
65. Al Tahan AM, Marwah M, El-Zein H, Al Tahan S, Sanchez-Aranguren L. Exploring mesoporous silica microparticles in pharmaceutical sciences: drug delivery and therapeutic insights. Int J Pharm. 2025;678:125656. https://doi.org/10.1016/j.ijpharm.2025.125656.10.1016/j.ijpharm.2025.125656 ↗
66. Al Tahan MA, Michaelides K, Somasekharan Nair S, AlShatti S, Russell C, Al-Khattawi A. Mesoporous silica microparticle-protein complexes: effects of protein size and solvent properties on diffusion and loading efficiency. Br J Biomed Sci. 2024. https://doi.org/10.3389/bjbs.2024.13595.10.3389/bjbs.2024.13595 ↗
67. Zheng S, Tian Y, Ouyang J, Shen Y, Wang X, Luan J. Carbon nanomaterials for drug delivery and tissue engineering. Front Chem. 2022. https://doi.org/10.3389/fchem.2022.990362.10.3389/fchem.2022.990362 ↗
68. Malode SJ, Pandiaraj S, Alodhayb A, Shetti NP. Carbon nanomaterials for biomedical applications: progress and outlook. ACS Appl Bio Mater. 2024;7(2):752–77. https://doi.org/10.1021/acsabm.3c00983.10.1021/acsabm.3c00983 ↗
69. Perini HF, Matos BS, de Oliveira CJF, da Silva MV. Biomimetic nanocarriers: integrating natural functions for advanced therapeutic applications. Beilstein J Nanotechnol. 2024;15:1619–26. https://doi.org/10.3762/bjnano.15.127.10.3762/bjnano.15.127 ↗
70. Tikhonov A, Kachanov A, Yudaeva A, et al. Biomimetic nanoparticles for basic drug delivery. Pharmaceutics. 2024;16(10):1306. https://doi.org/10.3390/pharmaceutics16101306.10.3390/pharmaceutics16101306 ↗
71. Chehelgerdi M, Chehelgerdi M, Allela OQB, et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023;22(1):169. https://doi.org/10.1186/s12943-023-01865-0.10.1186/s12943-023-01865-0 ↗
72. Harishchandra VB. Nanoparticle-based drug delivery systems: design strategies, formulation advances, mechanistic insights, clinical applications, and translational challenges. Asian J Res Med Med Sci. 2026;8(1):18–44. https://doi.org/10.56557/ajrmms/2026/v8i192.10.56557/ajrmms/2026/v8i192 ↗
73. Masoero A, Conte M, Percivalle NM, et al. Designing drug delivery systems: the impact of structural order and disorder for optimized therapeutic outcomes. Nanomedicine. 2026;21(4):541–72. https://doi.org/10.1080/17435889.2026.2615102.10.1080/17435889.2026.2615102 ↗
74. Hughes KJ, Ganesan M, Tenchov R, et al. Nanoscience in action: unveiling emerging trends in materials and applications. ACS Omega. 2025;10(8):7530–48. https://doi.org/10.1021/acsomega.4c10929.10.1021/acsomega.4c10929 ↗
75. Chen X, Argandona SM, Melle F, Rampal N, Fairen-Jimenez D. Advances in surface functionalization of next-generation metal-organic frameworks for biomedical applications: design, strategies, and prospects. Chem. 2024;10(2):504–43. https://doi.org/10.1016/j.chempr.2023.09.016.10.1016/j.chempr.2023.09.016 ↗
76. Park J, Choi Y, Chang H, Um W, Ryu JH, Kwon IC. Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment. Theranostics. 2019;9(26):8073–90. https://doi.org/10.7150/thno.37198.10.7150/thno.37198 ↗
77. Izci M, Maksoudian C, Manshian BB, Soenen SJ. The use of alternative strategies for enhanced nanoparticle delivery to solid tumors. Chem Rev. 2021;121(3):1746–803. https://doi.org/10.1021/acs.chemrev.0c00779.10.1021/acs.chemrev.0c00779 ↗
78. Vagena IA, Malapani C, Gatou MA, Lagopati N, Pavlatou EA. Enhancement of EPR effect for passive tumor targeting: current status and future perspectives. Appl Sci Basel. 2025;15(6):3189. https://doi.org/10.3390/app15063189.10.3390/app15063189 ↗
79. Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers (Basel). 2019;11(5):640. https://doi.org/10.3390/cancers11050640.10.3390/cancers11050640 ↗
80. Shi P, Cheng Z, Zhao K, et al. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics. J Nanobiotechnology. 2023;21(1):103. https://doi.org/10.1186/s12951-023-01826-1.10.1186/s12951-023-01826-1 ↗
81. Marques AC, Costa PC, Velho S, Amaral MH. Lipid nanoparticles functionalized with antibodies for anticancer drug therapy. Pharmaceutics. 2023;15(1):216. https://doi.org/10.3390/pharmaceutics15010216.10.3390/pharmaceutics15010216 ↗
82. Sharma R, Borah SJ, Bhawna, et al. Functionalized peptide-based nanoparticles for targeted cancer nanotherapeutics: a state-of-the-art review. ACS Omega. 2022;7(41):36092–107. https://doi.org/10.1021/acsomega.2c03974.10.1021/acsomega.2c03974 ↗
83. Juan A, Cimas FJ, Bravo I, Pandiella A, Ocaña A, Alonso-Moreno C. An overview of antibody conjugated polymeric nanoparticles for breast cancer therapy. Pharmaceutics. 2020;12(9):802. https://doi.org/10.3390/pharmaceutics12090802.10.3390/pharmaceutics12090802 ↗
84. Yang C, He B, Zhang H, Wang X, Zhang Q, Dai W. IgG Fc affinity ligands and their applications in antibody-involved drug delivery: a brief review. Pharmaceutics. 2023;15(1):187. https://doi.org/10.3390/pharmaceutics15010187.10.3390/pharmaceutics15010187 ↗
85. Spada A, Gerber-Lemaire S. Surface functionalization of nanocarriers with anti-EGFR ligands for cancer active targeting. Nanomaterials. 2025;15(3):158. https://doi.org/10.3390/nano15030158.10.3390/nano15030158 ↗
86. Thalhauser S, Breunig M. Considerations for efficient surface functionalization of nanoparticles with a high molecular weight protein as targeting ligand. Eur J Pharm Sci. 2020;155:105520. https://doi.org/10.1016/j.ejps.2020.105520.10.1016/j.ejps.2020.105520 ↗
87. Rabaan AA, Bukhamsin R, AlSaihati H, et al. Recent trends and developments in multifunctional nanoparticles for cancer theranostics. Molecules. 2022;27(24):8659. https://doi.org/10.3390/molecules27248659.10.3390/molecules27248659 ↗
88. Lankoff AM, Czerwińska M, Kruszewski M. Advances in nanotheranostic systems for concurrent cancer imaging and therapy: an overview of the last 5 years. Molecules. 2024;29(24):5985. https://doi.org/10.3390/molecules29245985.10.3390/molecules29245985 ↗
89. Cole JT, Holland NB. Multifunctional nanoparticles for use in theranostic applications. Drug Deliv Transl Res. 2015;5(3):295–309. https://doi.org/10.1007/s13346-015-0218-2.10.1007/s13346-015-0218-2 ↗
90. El-Sayed Ellakwa D, Ellakwa TE. Biocompatible nanoparticles in medicine: from design to clinical translation. Discov Mater. 2025;6(1):28. https://doi.org/10.1007/s43939-025-00489-z.10.1007/s43939-025-00489-z ↗
91. Nelemans LC, Gurevich L. Drug delivery with polymeric nanocarriers—cellular uptake mechanisms. Materials. 2020;13(2):366. https://doi.org/10.3390/ma13020366.10.3390/ma13020366 ↗
92. Sousa de Almeida M, Susnik E, Drasler B, Taladriz-Blanco P, Petri-Fink A, Rothen-Rutishauser B. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem Soc Rev. 2021;50(9):5397–434. https://doi.org/10.1039/D0CS01127D.10.1039/D0CS01127D ↗
93. Li J, Murakami Y, Kakuta H, et al. Preparation of PLGA nanoparticles co-incorporated with protein and hydrophobic drugs as a formulation of oral immunotherapy. NANO. 2026. https://doi.org/10.1142/S1793292025501061.10.1142/S1793292025501061 ↗
94. Ejazi SA, Louisthelmy R, Maisel K. Mechanisms of nanoparticle transport across intestinal tissue: an oral delivery perspective. ACS Nano. 2023;17(14):13044–61. https://doi.org/10.1021/acsnano.3c02403.10.1021/acsnano.3c02403 ↗
95. Richards CJ, Burgers TCQ, Vlijm R, Roos WH, Åberg C. Rapid internalization of nanoparticles by human cells at the single particle level. ACS Nano. 2023;17(17):16517–29. https://doi.org/10.1021/acsnano.3c01124.10.1021/acsnano.3c01124 ↗
96. Mazumdar S, Chitkara D, Mittal A. Exploration and insights into the cellular internalization and intracellular fate of amphiphilic polymeric nanocarriers. Acta Pharm Sin B. 2021;11(4):903–24. https://doi.org/10.1016/j.apsb.2021.02.019.10.1016/j.apsb.2021.02.019 ↗
97. Narum S, Deal B, Ogasawara H, Mancuso JN, Zhang J, Salaita K. An endosomal escape trojan horse platform to improve cytosolic delivery of nucleic acids. ACS Nano. 2024;18(8):6186–201. https://doi.org/10.1021/acsnano.3c09027.10.1021/acsnano.3c09027 ↗
98. Desai N, Rana D, Salave S, Benival D, Khunt D, Prajapati BG. Achieving endo/lysosomal escape using smart nanosystems for efficient cellular delivery. Molecules. 2024;29(13):3131. https://doi.org/10.3390/molecules29133131.10.3390/molecules29133131 ↗
99. Chahal G, Helbig K, Parton R, Monson E. The biology of endosomal escape: strategies for enhanced delivery of therapeutics. ACS Nano. 2026;20(2):1789–813. https://doi.org/10.1021/acsnano.5c18112.10.1021/acsnano.5c18112 ↗
100. He B, Sui X, Yu B, Wang S, Shen Y, Cong H. Recent advances in drug delivery systems for enhancing drug penetration into tumors. Drug Deliv. 2020;27(1):1474–90. https://doi.org/10.1080/10717544.2020.1831106.10.1080/10717544.2020.1831106 ↗